FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W176164021> ?p ?o ?g. }

• W176164021 endingPage "2" @default.
• W176164021 startingPage "SCI" @default.
• W176164021 abstract "The intersection of the availability of genetically altered mice, new technologies for intravital microscopy and high speed computing systems has led to the use of animal models to build on the concepts that have emerged from in vitro studies of the molecular and cellular biology of hemostasis and thrombosis. In an effort to improve the understanding of the etiology and pathogenesis of thrombosis, thrombus formation has been initiated in experimental systems via mechanical disruption, laser-induced, photochemical-induced and ferric chloride-induced injury to the vessel wall, among others. None of these methods are physiologic, and as such, remain models that require extrapolation from a living animal – a mouse – to human biology. We have focused on laser-induced injury of the arteriole vessel wall in the cremasteric muscle of the mouse. Using high speed digital imaging of fluorescently labeled components and real time intravital microscopy, our group has been able to demonstrate that platelet accumulation and fibrin generation during thrombus formation occur simultaneously, that tissue factor and collagen are independent initiators of platelet activation, and that monocyte-derived microparticles deliver tissue factor to the site of thrombus development. Perhaps the most important and unanticipated observation has been that thiol isomerases, thought only to be involved in protein biosynthesis via the formation of disulfide bonds in the endoplasmic reticulum, play a critical role in thrombus formation. Protein disulfide isomerase (PDI), ERp5 and ERp57 are among the vascular thiol isomerases that are known to be important for the initiation of thrombus formation. Laser-induced thrombosis in mice is associated with PDI, ERp5 and ERp57 secretion by platelets and endothelium. Inhibition of these thiol isomerases blocks platelet thrombus formation and fibrin generation. The integrins αIIbβ3 and αVβ3 play a key role in this process, binding directly with the secreted thiol isomerases and capturing them in the vicinity of vessel wall injury. These enzymes are required for the initiation of platelet thrombus formation and fibrin generation, but the mechanism by which they function remains to be elucidated. At present, it would appear that there is an electron transfer pathway involving these enzymes that regulates the initiation of thrombus formation. The mechanism by which PDI participates in thrombus generation is being evaluated by using trapping mutant forms to identify substrates of PDI that participate in the network pathways linking thiol isomerases, platelet receptor activation and fibrin generation. Several proteins, including vitronectin, thrombospondin and Factor V, have been identified as forming covalent disulfide intermediates with PDI. We are currently exploring PDI as an antithrombotic target using isoquercetin and quercetin 3-rutinoside, inhibitors of PDI identified by high throughput screening. Tail bleeding times are equivalent for mice treated with quercetin-3-rutinoside and isoquercetin compared to untreated mice. In an in vivo mouse pulmonary embolism model, PDI inhibitors rescue a high percentage of mice from death. The b-domain of PDI binds to quercetin-3-rutinoside, and infusion of the isolated b’ domain into a mouse treated with quercetin-3-rutinoside restores thrombus formation. This suggests a method for reversal of bleeding if these PDI inhibitors are found to be complicated by bleeding. The antithrombotic properties of quercetin and isoquercetin in humans have been tested. A pharmacokinetic study with quercetin and isoquercetin determined optimal oral delivery with isoquercetin. The effectiveness of these PDI inhibitors in human studies is being evaluated in a clinical trial evaluating prophylaxis of thromboembolic events in patients with cancer-associated thrombosis. PDI is a novel target for antithrombotic therapy and is unique in that its inhibition simultaneously blocks platelet thrombus formation and fibrin generation. Disclosures Zwicker: Quercegen Pharma: Research Funding." @default.
• W176164021 created "2016-06-24" @default.
• W176164021 creator A5007341838 @default.
• W176164021 creator A5028221234 @default.
• W176164021 creator A5057286617 @default.
• W176164021 creator A5066321804 @default.
• W176164021 date "2014-12-06" @default.
• W176164021 modified "2023-09-27" @default.
• W176164021 title "Animal Models of Arterial and Venous Thrombosis" @default.
• W176164021 doi "https://doi.org/10.1182/blood.v124.21.sci-2.sci-2" @default.
• W176164021 hasPublicationYear "2014" @default.
• W176164021 type Work @default.
• W176164021 sameAs 176164021 @default.
• W176164021 citedByCount "1" @default.
• W176164021 countsByYear W1761640212017 @default.
• W176164021 crossrefType "journal-article" @default.
• W176164021 hasAuthorship W176164021A5007341838 @default.
• W176164021 hasAuthorship W176164021A5028221234 @default.
• W176164021 hasAuthorship W176164021A5057286617 @default.
• W176164021 hasAuthorship W176164021A5066321804 @default.
• W176164021 hasConcept C126322002 @default.
• W176164021 hasConcept C12722491 @default.
• W176164021 hasConcept C142724271 @default.
• W176164021 hasConcept C158617107 @default.
• W176164021 hasConcept C185592680 @default.
• W176164021 hasConcept C186738567 @default.
• W176164021 hasConcept C203014093 @default.
• W176164021 hasConcept C2776354463 @default.
• W176164021 hasConcept C2778382381 @default.
• W176164021 hasConcept C2778589496 @default.
• W176164021 hasConcept C2780868729 @default.
• W176164021 hasConcept C2781362458 @default.
• W176164021 hasConcept C2859252 @default.
• W176164021 hasConcept C5098756 @default.
• W176164021 hasConcept C54173615 @default.
• W176164021 hasConcept C71924100 @default.
• W176164021 hasConcept C86803240 @default.
• W176164021 hasConcept C89560881 @default.
• W176164021 hasConcept C95444343 @default.
• W176164021 hasConceptScore W176164021C126322002 @default.
• W176164021 hasConceptScore W176164021C12722491 @default.
• W176164021 hasConceptScore W176164021C142724271 @default.
• W176164021 hasConceptScore W176164021C158617107 @default.
• W176164021 hasConceptScore W176164021C185592680 @default.
• W176164021 hasConceptScore W176164021C186738567 @default.
• W176164021 hasConceptScore W176164021C203014093 @default.
• W176164021 hasConceptScore W176164021C2776354463 @default.
• W176164021 hasConceptScore W176164021C2778382381 @default.
• W176164021 hasConceptScore W176164021C2778589496 @default.
• W176164021 hasConceptScore W176164021C2780868729 @default.
• W176164021 hasConceptScore W176164021C2781362458 @default.
• W176164021 hasConceptScore W176164021C2859252 @default.
• W176164021 hasConceptScore W176164021C5098756 @default.
• W176164021 hasConceptScore W176164021C54173615 @default.
• W176164021 hasConceptScore W176164021C71924100 @default.
• W176164021 hasConceptScore W176164021C86803240 @default.
• W176164021 hasConceptScore W176164021C89560881 @default.
• W176164021 hasConceptScore W176164021C95444343 @default.
• W176164021 hasIssue "21" @default.
• W176164021 hasLocation W1761640211 @default.
• W176164021 hasOpenAccess W176164021 @default.
• W176164021 hasPrimaryLocation W1761640211 @default.
• W176164021 hasRelatedWork W141749963 @default.
• W176164021 hasRelatedWork W2142809579 @default.
• W176164021 hasRelatedWork W2318640698 @default.
• W176164021 hasRelatedWork W2434105999 @default.
• W176164021 hasRelatedWork W2492982476 @default.
• W176164021 hasRelatedWork W2575679046 @default.
• W176164021 hasRelatedWork W2789655943 @default.
• W176164021 hasRelatedWork W2944221021 @default.
• W176164021 hasRelatedWork W4323826591 @default.
• W176164021 hasRelatedWork W96873760 @default.
• W176164021 hasVolume "124" @default.
• W176164021 isParatext "false" @default.
• W176164021 isRetracted "false" @default.
• W176164021 magId "176164021" @default.
• W176164021 workType "article" @default.